About

About Sio

Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease.

Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.

Our mission is simple:

To combine cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. We are working tirelessly to advance our rare fatal pediatric and adult neurodegenerative programs into clinical development so that patients can access the therapies they need.

Management

Our team is made up of leading scientific and gene therapy experts with decades of experience in all stages of drug development and commercialization. Our leaders are passionate about treating life-limiting neurodegenerative diseases on behalf of patients and their families.

Pavan Cheruvu, MD
Pavan Cheruvu, MD
Chief Executive Officer
Gavin Corcoran, MD
Gavin Corcoran, MD
Chief R&D Officer
David Nassif, JD
David Nassif, JD
Chief Financial Officer & General Counsel
Parag Meswani, PharmD
Parag Meswani, PharmD
Chief Commercial Officer
Sean O’Bryan
Sean O’Bryan
Senior Vice President, Regulatory Affairs

Board of Directors

Frank Torti, MD

Frank Torti, MD

Chairperson of the Board of Directors
Atul Pande, MD

Atul Pande, MD

Lead Independent Director
Eric Venker, MD

Eric Venker, MD, PharmD

Pavan Cheruvu, MD

Pavan Cheruvu, MD

Chief Executive Officer
Kristiina Vuori, MD, Ph.D.

Kristiina Vuori, MD, Ph.D.

Berndt Modig

Berndt Modig

Senthil Sundaram

Senthil Sundaram

Partners

partners handshakeSio Gene Therapies believes that patients deserve long-lasting, transformative therapies, not just incremental improvements. We see the potential in harnessing the power of gene therapies to deliver better options for patients and believe that collaborations with other leaders in the field will get us there faster. We look for partners who share our same vision and are driven by the same urgency to deliver new gene therapies to patients. If you are interested in working with us, please contact us at info@siogtx.com.

Sio is proud to partner with the following organizations to accelerate the development of our transformative gene therapies:

Learn more about various leading patient organizations.

Scroll to Top